Prothena Corp. (NASDAQ:PRTA) fell 2.8% on Monday . The company traded as low as $56.01 and last traded at $56.33, with a volume of 182,651 shares changing hands. The stock had previously closed at $57.98.

A number of brokerages have recently weighed in on PRTA. Barclays PLC boosted their price objective on shares of Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, August 4th. Wedbush reissued an “outperform” rating and set a $77.00 price objective on shares of Prothena Corp. in a report on Wednesday, August 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $95.00 price objective on shares of Prothena Corp. in a report on Monday, July 18th. Credit Suisse Group AG reissued a “buy” rating on shares of Prothena Corp. in a report on Friday, June 10th. Finally, Zacks Investment Research raised shares of Prothena Corp. from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Prothena Corp. currently has an average rating of “Buy” and an average target price of $76.60.

The stock’s 50-day moving average price is $46.91 and its 200-day moving average price is $42.24. The firm’s market capitalization is $1.95 billion.

Prothena Corp. (NASDAQ:PRTA) last released its earnings results on Tuesday, August 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.91) by $0.27. The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.39 million. The company’s revenue for the quarter was up 22.2% compared to the same quarter last year. Analysts anticipate that Prothena Corp. will post ($4.25) EPS for the current fiscal year.

In other Prothena Corp. news, Director Dennis J. Selkoe sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $45.00, for a total transaction of $225,000.00. Following the sale, the director now directly owns 3,025 shares in the company, valued at approximately $136,125. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Arthur W. Homan sold 9,375 shares of the stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total transaction of $488,812.50. Following the sale, the insider now owns 9,375 shares in the company, valued at $488,812.50. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. Jennison Associates LLC raised its stake in Prothena Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 406,677 shares of the company’s stock worth $27,699,000 after buying an additional 1,912 shares during the period. Wells Fargo & Company MN raised its stake in Prothena Corp. by 2,138.8% in the fourth quarter. Wells Fargo & Company MN now owns 245,639 shares of the company’s stock worth $16,730,000 after buying an additional 234,667 shares during the period. Morgan Stanley raised its stake in Prothena Corp. by 10.8% in the fourth quarter. Morgan Stanley now owns 18,747 shares of the company’s stock worth $1,278,000 after buying an additional 1,830 shares during the period. New York State Common Retirement Fund raised its stake in Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock worth $2,111,000 after buying an additional 1,200 shares during the period. Finally, California Public Employees Retirement System raised its stake in Prothena Corp. by 214.0% in the fourth quarter. California Public Employees Retirement System now owns 91,700 shares of the company’s stock worth $6,246,000 after buying an additional 62,500 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.